Skip to main content
Log in

Determination of bevantolol in human plasma by high performance liquid chromatography using solid phase extraction technique

  • Article
  • Drug development
  • Published:
Archives of Pharmacal Research Aims and scope Submit manuscript

Abstract

A method was developed and fully validated for the determination of bevantolol, an adrenergic-receptor blocker, in human plasma. Bevantolol and betaxolol as internal standard (I.S) were extracted from 1mL of human plasma by solid phase extraction technique using Sep-pak silica cartridge. Chromatographic separation was accomplished under isocratic conditions using a reverse-phase C8 analytical column and mixture of dibasic ammonium phosphate (pH 5.7; 50mM)-acetonitrile (75:25, v/v) as mobile phase, with a detection wavelength at 220 nm. The method was proved to be specific by testing six different human plasma sources. Linearity was established for the concentration ranges of 40-1600 ng/mL with correlation coefficent of 0.9995. The lower limit of quantification 40 ng/mL with precision of 10.9% as C.V%.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Duke, I. D. and Williams, E. M., Cardiovascular effects of bevantolol, a selective β1-adrenoceptor antagonist with a novel pharmacological profile.Br. J. Pharmacol., 84, 365–380 (1985).

    Google Scholar 

  • Guidance for industry. Bioanalytical Method Validation. U.S Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER)(2001).

  • Guidance for industry. Bioavailability and Bioequivalence Studies for orally Administered Drug Products: General Considerations. U.S Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) (2003).

  • Hastings, S. G, Smith, R. D., Corey, R. M., Essenburg, A. D., Pettway, C. E., and Tessman, D. K., Pharmacologic evalution of CI-775, a cardioselective beta-adrenergic antagonist.Arch. Int. Pharmacodyn., 226, 81–99 (1977).

    PubMed  CAS  Google Scholar 

  • Hoefle, M. L, Hastings, S. G, Meyer, R. F., Corey, R. M., Holmes, A., and Stratton, C. D., Cardioselective beta-adrenergic blocking agents. 1: 1-[(3,4-dimethoxyphenethyl)-amino]-3-aryloxy-2-propanols.J. Med. Chem., 18, 148–152 (1975).

    Article  PubMed  CAS  Google Scholar 

  • Lofdahl, C, Svedmyr, K., and Svedmyr, N., Selectivity of bevantolol hydrochloride, a β1-adrenoceptor antagonist, in asmatic patient.Pharmacotherapy, 4, 205–210 (1984).

    PubMed  CAS  Google Scholar 

  • Mackay, A. D., Gribbin, H. R., Baldwin, C. J., and Tattersfield, A. E., Assessment of bronchial beta-blockade after oral bevantolol.Clin. Pharmacol. Ther, 29, 1–6 (1981).

    PubMed  CAS  Google Scholar 

  • Nation, R. L, Peng, G W., and Chiou, W. L, High pressure liquid Chromatographic method for simultaneous quantitative analysis of propranolol and 4-hydroxypropranolol in plasma.J. Chromatogr., 145, 429–436 (1978).

    Article  PubMed  CAS  Google Scholar 

  • Pico, Y, Blasco, C, and Font, G, Environmental and food applications of LC-tandem mass spectrometry in pesticideresidue analysis: an overview.Mass Spectro. Reviews, 23, 45–85 (2004).

    Article  CAS  Google Scholar 

  • Randinitis, E. J., Nelson, C., and Kinkel, A. W., Gas chromatographic determination of bevantolol in plasma.J. Chromatogr., 308, 345–349 (1984).

    Article  PubMed  CAS  Google Scholar 

  • Selen, A, Kinkel, A. W., Darke, A. C, Greene, D. S, and Welling, P. G, Comparative single dose and steady-state pharmacokinetics of bevantolol in young and elderly subjects.Eu. J. Clin Pharmacol, 30, 699–704 (1986).

    Article  CAS  Google Scholar 

  • Steen, S. N., Smith, R. L, Ginzton, L. E., and Criley, J. M., Bevantolol in treatment of anagina pectoris.Chest, 76, 368 (1979).

    Google Scholar 

  • Steen, S. N., Smith, R. L, Ginzton, L. E., Criley, J. M., and Blouin, L. T., Bevantolol as long-term antianginal therapy.Pharmacologist, 22, 191 (1980).

    Google Scholar 

  • Steven, E. R. and Randinitis, E. J., A high-performance liquid Chromatographie assay for the enantiomers of bevantolol in human plasma.Pharm. Research, 8, 758–762 (1991).

    Article  Google Scholar 

  • Vermeij, P. and Brummelen, P. V, Pharmacokinetic parameters of bevantolol in volunteers.EurJ. Clin. Pharmacol., 30, 375–377 (1986).

    Article  CAS  Google Scholar 

  • Yamamoto, M., Takayanagi Y, Nihashi, S., Nomura, Y, and Nohira, H., Bevantolol hydrochloride (nc-1400): Absolute configuration and direct separation of the enantiomers.Chirality 7, 572–574 (1995).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kyeong Ho Kim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Trung, T.Q., Long, P.H., Al-Abd, A.M. et al. Determination of bevantolol in human plasma by high performance liquid chromatography using solid phase extraction technique. Arch Pharm Res 30, 890–897 (2007). https://doi.org/10.1007/BF02978842

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02978842

Key words

Navigation